HG-14-10-04 is a novel, potent and specific ALK (Anaplastic lymphoma kinase) inhibitor with IC50 of 20 The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL).

Entrectinib (formerly also known as NMS-E628; RXDX-101; trade name ROZLYTREK) is a potent and orally bioavailable small molecule inhibitor of TrkA, TrkB, TrkC, ROS1 and ALK with potential antitumor activity.

CEP-28122 is a novel, potent, selective and orally bioavailable ALK inhibitor with a favorable pharmacodynamic and pharmacokinetic profile and robust and selective pharmacologic efficacy against ALK-positive human cancer cells and tumor xenograft models in mice.

Brigatinib analog is a derivative of Brigatinib (AP-26113; Alunbrig), which is an orally bioavailable ALK (anaplastic lymphoma kinase) inhibitor approved by FDA in 2017 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC).

SAR348830 (SAR-348830; SAR 348830) is potent and selective inhibitor of anaplastic lymphoma kinase (ALK ) with the potential to be used for treating Non-small Cell Lung Cancer.

Alectinib HCl (formerly AF802, CH5424802 or RO5424802; trade name ALECENSA) is a potent, selective, and orally bioavailable inhibitor of ALK (anaplastic lymphoma kinase) tyrosine kinase with IC50 value of 1.9 nM in cell-free assays.

KRCA-0008 is a novel, potent dual inhibitor of Ack1 and anaplastic lymphoma kinase (ALK) with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.

Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Belizatinib, formerly known as TSR-011, is a potent, orally bioavailable dual inhibitor of ALK (anaplastic lymphoma kinase) with IC50 of 0.7 nM and an inhibitor of tropomyosin receptor kinase (TRK) with IC50 values less than 3 nM for TRK A, B, and C.

AZD-3463 (AZD3463) is a novel, potent and selective ALK/IGF1R inhibitor with potential anticancer activity.